GAMMA Investing LLC boosted its position in shares of Balchem Co. (NASDAQ:BCPC - Free Report) by 20,231.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 177,288 shares of the basic materials company's stock after acquiring an additional 176,416 shares during the period. GAMMA Investing LLC owned about 0.54% of Balchem worth $29,430,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the company. Versant Capital Management Inc increased its holdings in Balchem by 534.2% in the first quarter. Versant Capital Management Inc now owns 241 shares of the basic materials company's stock valued at $40,000 after buying an additional 203 shares during the last quarter. Mackenzie Financial Corp boosted its position in shares of Balchem by 2.2% during the 4th quarter. Mackenzie Financial Corp now owns 3,840 shares of the basic materials company's stock worth $626,000 after acquiring an additional 84 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Balchem in the 4th quarter valued at about $3,246,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Balchem by 9.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 91,742 shares of the basic materials company's stock worth $14,953,000 after acquiring an additional 8,091 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its stake in Balchem by 41.0% during the fourth quarter. Voloridge Investment Management LLC now owns 26,178 shares of the basic materials company's stock worth $4,267,000 after purchasing an additional 7,608 shares during the last quarter. 87.91% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. Sidoti upgraded shares of Balchem to a "hold" rating in a research note on Tuesday, February 25th. Wall Street Zen downgraded shares of Balchem from a "buy" rating to a "hold" rating in a research note on Wednesday, May 21st. Finally, HC Wainwright set a $180.00 target price on Balchem and gave the stock a "buy" rating in a research report on Monday, April 28th.
View Our Latest Report on Balchem
Balchem Stock Performance
NASDAQ BCPC traded up $0.68 on Friday, reaching $166.22. The stock had a trading volume of 100,946 shares, compared to its average volume of 138,703. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.16 and a current ratio of 1.99. The stock has a market cap of $5.42 billion, a P/E ratio of 42.30, a price-to-earnings-growth ratio of 4.41 and a beta of 0.93. The business's 50-day moving average price is $162.18 and its 200 day moving average price is $165.51. Balchem Co. has a 12-month low of $145.70 and a 12-month high of $186.03.
Balchem (NASDAQ:BCPC - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The basic materials company reported $1.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.25 by ($0.03). The business had revenue of $250.52 million for the quarter, compared to analysts' expectations of $245.70 million. Balchem had a return on equity of 11.37% and a net margin of 13.47%. The company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.03 earnings per share. As a group, equities analysts expect that Balchem Co. will post 4.64 earnings per share for the current year.
Balchem Company Profile
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Stories
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
